Q4 2024 QuidelOrtho Corp Earnings Call Transcript
Key Points
- QuidelOrtho Corp (QDEL) achieved solid top-line results in 2024, aligning with their financial guidance.
- The company reported over 90% of Q4 sales as recurring, driven by reagents, consumables, and service.
- The Labs business, which constitutes about 50% of total company revenues, showed a growth of 4% excluding COVID and non-core revenue.
- QuidelOrtho Corp (QDEL) initiated clinical trials for the Savanna Respiratory Panel, aiming to complete them in the upcoming months.
- The company is implementing cost reduction initiatives, expecting to drive margin growth over the next few years to achieve benchmark levels of profitability.
- Total reported revenue in Q4 2024 decreased by 4% year-over-year due to expected declines in COVID and flu testing revenues.
- Adjusted EBITDA for Q4 2024 was $150 million, down from $195 million in the prior year period.
- North America revenue declined by 11% in Q4 2024, impacted by the decline in respiratory revenue and U.S. donor screening revenue.
- Adjusted gross profit margin decreased to 47% in Q4 2024 from 52% in the prior year period, primarily due to lower COVID and flu sales.
- The company faces challenges in China due to competitive intensity and reimbursement changes, impacting cardiac point of care products.
Welcome to the QuidelOrtho Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast. At this time, all participant lines are in a listen-only mode. (Operator Instructions)
I would now like to turn the call over to Juliet Cunningham, Vice President of Investor Relations.
Thank you. Good afternoon, everyone.
Thanks for joining the QuidelOrtho's fourth quarter and full year 2024 financial results conference call. With me today are Brian Blaser, President and Chief Executive Officer; and Joe Busky, Chief Financial Officer. This conference call is being simultaneously webcast on the Investor Relations page of our website. To aid in the discussion, we posted a supplemental presentation on the IR page that will be referenced throughout this call.
This conference call contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not strictly historical, including the company's expectations, plans,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
